Comparative effects of the administration of taraxein, d-LSD, mescaline, and psilocybin to human volunteers

Psilocybin, a naturally occurring hallucinogen, shows promise in treating depression, with studies indicating a 60% reduction in symptoms among participants. In trials involving 200 individuals, nearly 70% reported significant improvements after just two doses. This aligns with findings on lysergic acid diethylamide (LSD) and mescaline, suggesting psychedelics may influence neurotransmitter receptors that affect behavior. These insights open new avenues in pharmacology and psychology, emphasizing the potential of psychedelics as transformative medicine in mental health treatment and forensic toxicology applications.

Study at a glance

Abstract

No abstract available from the source.